Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection.
作者信息
Raedler Lisa A
出版信息
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):142-7.
Abstract
摘要
相似文献
1
Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection.维柯佳（奥比他韦、帕利瑞韦和利托那韦片；达沙布韦片）：全口服固定剂量组合药物，获批用于治疗基因1型慢性丙型肝炎感染。
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):142-7.
2
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.用于丙型肝炎病毒1型感染的奥比他韦/帕利哌韦/利托那韦和达沙布韦片
Ann Pharmacother. 2015 May;49(5):566-81. doi: 10.1177/1060028015570729. Epub 2015 Feb 13.
3
Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction.使用帕利瑞韦/利托那韦/奥米他韦和达沙布韦（VIEKIRA PAK®）治疗慢性丙型肝炎继发的药物性肺炎：一例危及生命的意外不良反应病例报告
Case Rep Med. 2017;2017:4895736. doi: 10.1155/2017/4895736. Epub 2017 Mar 20.
4
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.奥比他韦、帕利瑞韦、利托那韦、达沙布韦联合或不联合利巴韦林治疗丙型肝炎病毒基因型 1 或 4 感染合并肝硬化患者（ABACUS）：一项前瞻性观察研究。
Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.
5
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C.帕利瑞韦/利托那韦/奥比他韦加达拉他韦联合利巴韦林治疗慢性丙型肝炎
Aust Prescr. 2016 Aug;39(4):141-143. doi: 10.18773/austprescr.2016.045. Epub 2016 May 20.
6
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.奥比他韦/帕利瑞韦/利托那韦联合达萨布韦：慢性 HCV 基因 1 型感染治疗的研究进展。
Drugs. 2015 Jun;75(9):1027-38. doi: 10.1007/s40265-015-0412-z.
7
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.帕利瑞韦/利托那韦、奥比他韦、达沙布韦联合治疗肝损伤患者的药代动力学和安全性。
J Hepatol. 2015 Oct;63(4):805-12. doi: 10.1016/j.jhep.2015.05.029. Epub 2015 Jun 10.
8
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.奥比他韦、帕立瑞韦、利托那韦和达沙布韦联合治疗 8 周，用于初治无肝硬化的 1b 型丙型肝炎病毒感染患者（GARNET）：一项单臂、开放标签、3b 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Jul;2(7):494-500. doi: 10.1016/S2468-1253(17)30071-7. Epub 2017 Apr 14.
9
Ombitasvir-Paritaprevir-Ritonavir-Dasabuvir (Viekira Pak)-Induced Lactic Acidosis.奥比他韦-帕立他韦-利托那韦-达沙布韦（维建乐）诱发的乳酸性酸中毒。
Crit Care Med. 2017 Mar;45(3):e321-e325. doi: 10.1097/CCM.0000000000002086.
10
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.对于近期感染丙型肝炎病毒1型的患者，使用帕利瑞韦/利托那韦/奥米他韦和达沙布韦进行为期八周的缩短疗程治疗具有很高的疗效。
J Viral Hepat. 2018 Oct;25(10):1180-1188. doi: 10.1111/jvh.12917. Epub 2018 May 8.
引用本文的文献
1
Unraveling the therapeutic landscape of approved non-peptide macrocycles.解析已获批非肽大环化合物的治疗前景。
Acta Pharm Sin B. 2025 Jul;15(7):3436-3459. doi: 10.1016/j.apsb.2025.04.021. Epub 2025 Apr 25.
2
Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals.规避传统抗病毒药物出现耐药性的策略与努力。
NPJ Antimicrob Resist. 2025 Jun 9;3(1):54. doi: 10.1038/s44259-025-00125-z.
3
ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of I.ABT-333（达沙布韦）通过抑制I增加犬左心室细胞的动作电位持续时间并引发早期后去极化。
Pharmaceuticals (Basel). 2023 Mar 25;16(4):488. doi: 10.3390/ph16040488.
4
The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands.荷兰近期入境移民中丙型肝炎病毒筛查策略的成本效益分析。
Int J Environ Res Public Health. 2020 Aug 21;17(17):6091. doi: 10.3390/ijerph17176091.
5
Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease.推特作为肝病趋势的非侵入性生物标志物
Hepatol Commun. 2019 Jul 13;3(9):1271-1280. doi: 10.1002/hep4.1394. eCollection 2019 Sep.
6
Era of direct acting anti-viral agents for the treatment of hepatitis C.用于治疗丙型肝炎的直接作用抗病毒药物时代。
World J Hepatol. 2018 Oct 27;10(10):670-684. doi: 10.4254/wjh.v10.i10.670.
7
Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.慢性丙型肝炎病毒（HCV）感染患者中，慢性肾脏病4期、终末期肾病或透析对奥比他韦、帕利瑞韦、利托那韦和达沙布韦血浆浓度的影响：3期RUBY - I和RUBY - II试验的药代动力学分析
Eur J Clin Pharmacol. 2019 Feb;75(2):207-216. doi: 10.1007/s00228-018-2566-6. Epub 2018 Oct 5.
8
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.帕利瑞韦、奥比他韦、达塞布韦、利托那韦和利巴韦林治疗丙型肝炎病毒感染的肝硬化和非肝硬化患者的群体药代动力学：九项 III 期研究的分析。
Clin Pharmacokinet. 2018 Nov;57(11):1407-1419. doi: 10.1007/s40262-018-0640-y.
9
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.奥比他韦/帕利瑞韦/利托那韦与达沙布韦联合或不联合利巴韦林治疗丙型肝炎病毒1型的安全性和有效性：一项系统评价和荟萃分析。
Clin Drug Investig. 2017 Nov;37(11):1009-1023. doi: 10.1007/s40261-017-0565-5.
10
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.慢性丙型肝炎病毒1型感染患者中ombitasvir、paritaprevir/ritonavir、dasabuvir和利巴韦林的暴露-安全性反应关系：来自五项II期和六项III期研究的数据分析
Clin Drug Investig. 2017 Jul;37(7):647-657. doi: 10.1007/s40261-017-0520-5.
本文引用的文献
1
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.ABT-450/r-ombitasvir 和 dasabuvir 联合或不联合利巴韦林治疗 HCV。
N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.
2
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗肝硬化合并丙型肝炎。
N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11.
3
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和利巴韦林联合治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10.
4
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.
5
Current and future disease progression of the chronic HCV population in the United States.美国慢性 HCV 人群的当前和未来疾病进展。
PLoS One. 2013 May 21;8(5):e63959. doi: 10.1371/journal.pone.0063959. Print 2013.
6
Direct-acting antiviral agents for hepatitis C virus infection.直接作用抗病毒药物治疗丙型肝炎病毒感染。
Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5.
7
Current prospects for interferon-free treatment of hepatitis C in 2012.2012 年无干扰素治疗丙型肝炎的现状。
J Gastroenterol Hepatol. 2013 Jan;28(1):38-45. doi: 10.1111/jgh.12028.
8
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.治疗丙型肝炎：现行的标准护理和新兴的直接作用抗病毒药物。
J Viral Hepat. 2012 Jul;19(7):449-64. doi: 10.1111/j.1365-2893.2012.01617.x.
9
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.美国丙型肝炎病毒 (HCV) 感染者的老龄化：HCV 流行率和疾病进展的多队列模型。
Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6. doi: 10.1053/j.gastro.2009.09.067. Epub 2009 Oct 25.
10
The global burden of hepatitis C.丙型肝炎的全球负担。
Liver Int. 2009 Jan;29 Suppl 1:74-81. doi: 10.1111/j.1478-3231.2008.01934.x.
Zotero 插件